ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Pittsburgh Cancer Institute Gets NCI Core Grants

June 24, 1988

Rituxan Approved as Maintenance For Advanced Follicular Lymphoma

February 25, 2011

Hairy Cell Leukemia Patients Have CRs In Phase I Trial

September 28, 2001

Program Announcement; NCI Seeks Studies Of Breast Cancer In Northeast U.S.

January 22, 1993

Concepts Approved for Primary Care, Worker Health, Black Interventions

May 17, 1985

Afinitor Extends PFS In Women With EGFR-2 Positive Disease

June 28, 2013